Clinical Studies | UCB
UCB's Global Corporate Website

Welcome to our
Clinical Studies section

Clinical studies involving healthy volunteers and patients play a vital role in the development of new drugs. These studies are conducted to ensure that all investigational drugs are safe and effective. Over recent years, along with drug discovery, drug development and clinical studies have benefitted from scientific and technological advancements as well as a greater understanding of the needs clinical study participants have.

At UCB we’ve moved away from seeing patients as just patients. By really listening and engaging with them as partners we are striving for greater understanding of their needs or ways to improve our clinical studies. To improve and accelerate development, we will keep patients’ needs front and center, leverage new technologies, and adaptive clinical study design to improve the patient experience.

Diversification of clinical trials is critical, and UCB is working to increase representation and inclusion of underrepresented patient populations through digital and data-driven approaches as well as connecting directly to patient communities. We are committed to working toward a clinical trials infrastructure that addresses health disparities and closes the gap in clinical trial diversity to better reflect the intended treatment population. We continue our work to identify best practices around key drivers such as scientific rigor, informing innovation, and addressing health inequities in clinical trials now and into the future.


Current clinical studies at a glance

Find out more about a selection of studies

Atopic Dermatitis - UP0089 Study

The UP0089 Study (

A Phase I/IIA, Randomized, Placebo-Controlled, Single-Ascending Dose (Part A, Participant- and Investigator-Blind) and Repeated-Dose (Part B, Participant-, Investigator-, and Sponsor-Blind) Study to Investigate the Safety, Pharmacokinetics, and Efficacy of UCB9741 in Healthy Study Participants (Part A) and in Study Participants With Moderate-to-Severe Atopic Dermatitis (Part B)

Juvenile absence epilepsy - EXPAND study - N01269

A Randomized, Dose-Finding and Confirmatory, Double-Blind, Placebo-Controlled, Parallel-Group Multicenter Study With a 2 Stage Adaptive Design and Randomized Withdrawal to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

Myelin oligodendrocyte glycoprotein antibody-associated disease (MOG-AD) - "cosMOG" study - MOG001

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3, Pivotal Study With an Open-Label Extension Period to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-Associated Disease (MOG-AD)

Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis - "LEGIONE" study - AIE001

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Rozanolixizumab in Adult Study Participants With Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis

Stereotypical prolonged seizures - "STARS" study - EP0162

A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Outpatient, Parallel-Group Study to Assess the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

Stereotypical prolonged seizures - "STARS extension" study - EP0165

An Open-Label, Multicenter, Outpatient Extension Study to Evaluate the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

Enrolling by invitation
Parkinson’s Disease - "Orchestra" study - PD0053

Orchestra study website

A Double-Blind, Placebo-Controlled, Randomized, 18-Month Phase 2a Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral UCB0599 in Study Participants With Early Parkinson’s Disease

Systemic lupus erythematosus - "PHOENYCS GO" study - SL0043

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

Moderate to Severe Chronic Plaque Psoriasis - "CIMCare" study - PS0007

Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled (12-17 Years) Including a Single Open-Label Arm (6-11 Years) Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol (CZP) in Pediatric Study Participants With Moderate to Severe Chronic Plaque Psoriasis (PSO)


Discover more about our clinical studies

Interested in enrolling in our study?

Just contact us

+43 (0) 1 291 80 08
0800-296176 (freephone)

+32 2 559 92 00
0800 38 008 (freephone)

+359 2 962 9933


+1 866 709 8444

Czech Republic
+420 221 773 442
800 144 395 (freephone)

+45 32462480
80 253827 (freephone)

+358 942733300
0800 9 13353 (freephone)

+33 1 47 29 45 55
0 805 222 949 (freephone)

+49 2173 48 48 48

+30 21 0997 4200
0080 012 9910 (freephone)

+36 1 472 5060
06 80 021 486 (freephone)

+353 1 463 2371
1800 93 00 75 (freephone)

+39 02 3007 9300
8009-86932 (freephone)

+32 2 559 92 12
8002 3204 (freephone)

+45 32462482
800-10101 (freephone)

+48 22 596 97 97
00 800 121 68 25 (freephone)

+351 213 025 300
800-8-56033 (freephone)


+4021 300 19 07

+421 2 592 020 23
0800 002 566 (freephone)

+34 915 70 06 49
8000-99684 (freephone)

+45 32462481
0200 898 671 (freephone)


+41 58 822 3180

The Netherlands
+31 76 573 1130
0800 3434335 (freephone)

+44 1753 777 100
0800 279 3177 (freephone)

People don't see my disease and how it threatents my independence,
and those same people don't realise that they, too, could be at risk.

Lut, living with osteoporosis

Disease resources